Recombinant adenovirus encoding FAT10 small interfering RNA inhibits HCC growth in vitro and in vivo

Experimental and Molecular Pathology

Volumn 96, Issue 2, 2014, Pages 207-211

  Chen, Jingxiang ^a   Yang, Li ^a   Chen, Hongxu ^a   Yuan, Tao ^a   Liu, Menggang ^a   Chen, Ping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Carcinogenesis; FAT10; HCC; RNA interference; Strategy

Indexed keywords

SMALL INTERFERING RNA; UBD PROTEIN, HUMAN; UBIQUITIN;

ADENOVIRIDAE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER NEOPLASMS; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; RNA, SMALL INTERFERING; UBIQUITINS;

EID: 84894280603     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.01.001     Document Type: Article

References (32)

1. Bates E.E., Ravel O., Dieu M.C., et al. Identification and analysis of a novel member of the ubiquitin family expressed in dendritic cells and mature B cells. Eur. J. Immunol. 1997, 27:2471-2477.
2. Bayer P., Arndt A., Metzger S., et al. Structure determination of the small ubiquitin-related modifier SUMO-1. J. Mol. Biol. 1998, 280:275-286.
3. Cabibbo G., Latteri F., Antonucci M., et al. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat. Clin. Pract. 2009, 6:159-169.
4. Carr B.I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004, 127:S218-S224.
5. Dai R.M., Li C.C. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat. Cell Biol. 2001, 3:740-744.
6. El-Serag H.B. Hepatocellular carcinoma: an epidemiologic view. J. Clin. Gastroenterol. 2002, 35:S72-S78.
7. Fatourou E.M., Koskinas J.S. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert. Rev. Anticancer. Ther. 2009, 9:1499-1510.
8. Hoffmann K., Schmidt J. New surgical approaches in the treatment of hepatocellular carcinoma. Z. Gastroenterol. 2009, 47:61-67.
9. Huang K.W., Huang Y.C., Tai K.F., et al. Dual therapeutic effects of interferon-alpha gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis. Mol. Ther. 2008, 16:1681-1687.
10. Ji F., Jin X., Jiao C.H., et al. FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging. World J. Gastroenterol. 2009, 15:2228-2233.
11. Lee C.G., Ren J., Cheong I.S., et al. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 2003, 22:2592-2603.
12. Lim C.B., Zhang D., Lee C.G. FAT10, a gene up-regulated in various cancers, is cell-cycle regulated. Cell Div. 2006, 1:20.
13. Liu Y.C., Pan J., Zhang C., et al. A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4313-4318.
14. Love K.R., Catic A., Schlieker C., et al. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat. Chem. Biol. 2007, 3:697-705.
15. Mann C.D., Neal C.P., Garcea G., et al. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur. J. Cancer Prev. 2009, 18:13-25.
16. Mucha S.R., Rizzani A., Gerbes A.L., et al. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. Gut 2009, 58:688-698.
17. Mulcahy M.F. Management of hepatocellular cancer. Curr. Treat. Options in Oncol. 2005, 6:423-435.
18. Murray R.Z., Norbury C. Proteasome inhibitors as anti-cancer agents. Anti-Cancer Drugs 2000, 11:407-417.
19. Nakamura T., Kimura T., Umehara Y., et al. Long-term survival after report resection of pulmonary metastases from hepatocellular carcinoma: report of two cases. Surg. Today 2005, 35:890-892.
20. Niguma T., Mimura T., Tutui N. Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. J. Hepato-Biliary-Pancreat. Surg. 2005, 12:249-253.
21. Oliva J., Bardag-Gorce F., French B.A., et al. Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. Exp. Mol. Pathol. 2008, 84:102-112.
22. Palmer D.H., Hussain S.A., Johnson P.J. Gene- and immunotherapy for hepatocellular carcinoma. Expert. Opin. Biol. Ther. 2005, 5:507-523.
23. Raasi S., Schmidtke G., Groettrup M. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J. Biol. Chem. 2001, 276:35334-35343.
24. Ren J., Kan A., Leong S.H., et al. FAT10 plays a role in the regulation of chromosomal stability. J. Biol. Chem. 2006, 281:11413-11421.
25. Reverter D., Lima C.D. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 2005, 435:687-692.
26. Shen Z., Wong O.G., Yao R.Y., et al. A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma. Cancer Lett. 2008, 272:268-276.
27. Su H.L., Li S.S. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 2002, 296:65-73.
28. Yu A.S., Keeffe E.B. Management of hepatocellular carcinoma. Rev. Gastroenterol. Disord. 2003, 3:8-24.
29. Zhang D.W., Jeang K.T., Lee C.G. p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. Oncogene 2006, 25:2318-2327.
30. Zhao J., Dong L., Lu B., et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135:956-968.
31. Zhu A.X. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?. Oncologist 2006, 11:790-800.
32. Ziparo V., Balducci G., Lucandri G., et al. Indications and results of resection for hepatocellular carcinoma. Eur. J. Surg. Oncol. 2002, 28:723-728.